Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Phase 2

Active, not recruiting

Conditions: Newly Diagnosed Ewing Sarcoma

Interventions: Drug: Cyclophosphamide
Device: Doxorubicin
Drug: Vincristine
Drug: Ifosfamide
Drug: Etoposide
Procedure: Surgery
Radiation: Radiation Therapy*
Drug: Temozolomide
Drug: Irinotecan
Drug: Mesna
Drug: Dexrazoxane
Drug: G-CSF

First Posted Date: 2013-05-29

Last Posted Date: 2024-11-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 83

Registration Number: NCT01864109

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Phase 2

Active, not recruiting

Conditions: Cholangiolar Carcinoma
Cholangiocellular Carcinoma
Peripheral Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma

Interventions: Drug: Floxuridine (FUDR)
Drug: dexamethasone
Drug: Gemcitabine
Drug: Oxaliplatin
Other: MRI
Other: Research blood draws

First Posted Date: 2013-05-24

Last Posted Date: 2024-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 55

Registration Number: NCT01862315

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 2 locations

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Phase 1

Active, not recruiting

Conditions: Relapsed B-Cell Acute Lymphoblastic Leukemia

Interventions: Procedure: leukapheresis or collection of PBMCs
Drug: cyclophosphamide based chemotherapy regimens
Biological: modified T cells

First Posted Date: 2013-05-23

Last Posted Date: 2024-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT01860937

Locations: 🇺🇸
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

Phase 3

Completed

Conditions: Invasive Breast Cancer

Interventions: Other: Eucerin
Other: Mometasone Furoate 0.1%

First Posted Date: 2013-05-17

Last Posted Date: 2019-10-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 143

Registration Number: NCT01856543

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Biological: Pegfilgrastim
Biological: 19-28z T CELLS
Procedure: Autologous Stem Cell Transplantation

First Posted Date: 2013-04-25

Last Posted Date: 2024-05-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01840566

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Phase 2

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sorafenib
Drug: Doxorubicin

First Posted Date: 2013-04-25

Last Posted Date: 2024-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01840592

Locations: 🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Phase 1

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Afatinib
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Radiation: Radiation therapy

First Posted Date: 2013-04-19

Last Posted Date: 2013-12-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01836341

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bortezomib
Drug: Acyclovir

First Posted Date: 2013-04-16

Last Posted Date: 2020-08-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01833143

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Breath Training Exercise for the Reduction of Chronic Dyspnea

Not Applicable

Completed

Conditions: Chronic Pulmonary Disorder

Interventions: Other: breathing techniques
Behavioral: Self-Administered Baseline and Transition Dyspnea Indexes

First Posted Date: 2013-04-15

Last Posted Date: 2018-07-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT01831388

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer

Not Applicable

Completed

Conditions: Rectal Cancer

Interventions: Procedure: Advanced MR Imaging

First Posted Date: 2013-04-12

Last Posted Date: 2017-06-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT01830582

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy